(Q39827658)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

main subject

angiogenesis inhibitor

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Joong Bae Ahn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Sun Young Rha

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Hyun Cheol Chung

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

Hei-Cheul Jeung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

5

Jae Kyung Roh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Kyung Soo Park

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Dal-Hyun Kim

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Chin Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

8 July 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

650-658

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).

2 February 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9287-8

Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9287-8

Suppression of cyclin D1 mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells

21 January 2018

1 reference

12 December 2020

General pharmacology of CKD-732, a new anticancer agent: effects on central nervous, cardiovascular, and respiratory system

1 reference

12 December 2020

AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle.

1 reference

12 December 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

12 December 2020

Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732.

1 reference

12 December 2020

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

12 December 2020

Mechanisms of angiogenesis

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

1 reference

12 December 2020

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

12 December 2020

Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

1 reference

12 December 2020

TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro

1 reference

12 December 2020

Surrogate markers in antiangiogenesis clinical trials

1 reference

12 December 2020

A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.

1 reference

12 December 2020

Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

1 reference

12 December 2020

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

1 reference

12 December 2020

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

12 December 2020

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I

1 reference

12 December 2020

Disposition and metabolism of the angiogenic moderator O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes

1 reference

12 December 2020

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

1 reference

12 December 2020

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

12 December 2020

Bevacizumab in the treatment of breast cancer: rationale and current data

1 reference

12 December 2020

Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin

1 reference

12 December 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

12 December 2020

10.1007/S10637-009-9287-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19585083%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference